BACKGROUND Cognitive dysfunction in epileptic patients is a high-incidence complication.Its mechanism is related to nervous system damage during seizures,but there is no effective diagnostic biomarker.Neuronal pentrax...BACKGROUND Cognitive dysfunction in epileptic patients is a high-incidence complication.Its mechanism is related to nervous system damage during seizures,but there is no effective diagnostic biomarker.Neuronal pentraxin 2(NPTX2)is thought to play a vital role in neurotransmission and the maintenance of synaptic plasticity.This study explored how serum NPTX2 and electroencephalogram(EEG)slow wave/fast wave frequency ratio relate to cognitive dysfunction in patients with epilepsy.AIM To determine if serum NPTX2 could serve as a potential biomarker for diagnosing cognitive impairment in epilepsy patients.METHODS The participants of this study,conducted from January 2020 to December 2021,comprised 74 epilepsy patients with normal cognitive function(normal group),37 epilepsy patients with cognitive dysfunction[epilepsy patients with cognitive dysfunction(ECD)group]and 30 healthy people(control group).The minimental state examination(MMSE)scale was used to evaluate cognitive function.We determined serum NPTX2 levels using an enzyme-linked immunosorbent kit and calculated the signal value of EEG regions according to the EEG recording.Pearson correlation coefficient was used to analyze the correlation between serum NPTX2 and the MMSE score.RESULTS The serum NPTX2 level in the control group,normal group and ECD group were 240.00±35.06 pg/mL,235.80±38.01 pg/mL and 193.80±42.72 pg/mL,respectively.The MMSE score was lowest in the ECD group among the three,while no significant difference was observed between the control and normal groups.In epilepsy patients with cognitive dysfunction,NPTX2 level had a positive correlation with the MMSE score(r=0.367,P=0.0253)and a negative correlation with epilepsy duration(r=−0.443,P=0.0061)and the EEG slow wave/fast wave frequency ratio value in the temporal region(r=−0.339,P=0.039).CONCLUSION Serum NPTX2 was found to be related to cognitive dysfunction and the EEG slow wave/fast wave frequency ratio in patients with epilepsy.It is thus a potential biomarker for the diagnosis of cognitive impairment in patients with epilepsy.展开更多
Objective: Coronary Artery Disease (CAD) would continue to concern medical society in the foreseeable future. Determining the extent of coronary luminal stenosis is a key factor in management of CAD. Methods presently...Objective: Coronary Artery Disease (CAD) would continue to concern medical society in the foreseeable future. Determining the extent of coronary luminal stenosis is a key factor in management of CAD. Methods presently used are costly and pose certain dangers, ranging from nephrotoxicity to death. Long Pentraxin or Pentraxin-3 (PTX3) has been used to predict survival or atherosclerotic process, but not to identify coronary stenosis. Calcium Score has been used to this end with some success. Methods: Individuals with chronic stable angina, without evidence of Myocardial Infarction (MI), who were categorized as intermediate-risk after completing a treadmill exercise test, according to Duke Protocol, underwent cardiac catheterization. In addition, blood samples were drawn for coronary sinus PTX3, and also PTX3, uric acid, high-sensitivity C-reactive protein (hs-CRP), cholesterol, glucose and High-Density Lipo-protein (HDL) in peripheral circulation. Calcium Scores were calculated using Agatston Score and non-contrast multi-slice CT scan. Participants were divided according to the number of stenotic coronary arteries (patent, one-, two-and three-vessel disease). Results: We found that PTX3 levels in coronary sinus and femoral vein correlated with each other, after log-transforming the values. Also we found that PTX3 levels and Calcium Scores differed among individuals with triple-vessel involvement and individuals without significant stenosis in any of coronary arteries. No significant differences were observed, regarding hs-CRP levels. Conclusion: PTX3 levels in periphery correlate with those in coronary arteries, and this variable can be measured with a less invasive procedure. In addition to Calcium Score, PTX3 levels are different in our four groups. The combined contribution of PTX3 and calcium score may help us identify individuals with significant coronary artery stenosis without needing to perform cardiac catheterization in a select group of patients.展开更多
Background Pentraxin 3 （PTX3） is expressed in the heart under inflammatory conditions and plays an important role in atherogenesis. Patients with increased PTX3 levels may suffer from higher rates of cardiac events....Background Pentraxin 3 （PTX3） is expressed in the heart under inflammatory conditions and plays an important role in atherogenesis. Patients with increased PTX3 levels may suffer from higher rates of cardiac events. Regulation of specific genes by promoter methylation is important in atherogenesis. The factors influencing PTX3 levels and the association between epigenetics and PTX3 levels have not been investigated. Methods Blood samples were collected from 64 patients admitted to the Department of Cardiology, 35 who had coronary artery disease （CAD）, and 29 who were CAD-free. Plasma levels of PTX3 were measured by ELISA. PTX3 promoter methylation was evaluated via methyl-specific PCR. The severity of coronary artery lesion was evaluated by angiography. Results The level of PTX3 promoter methylation in the CAD group was 62.69% ± 20.57%, significantly lower than that of the CAD-free group, which was 72.45% ± 11.84% （P = 0.03）. Lower PTX3 promoter methylation levels in the CAD group were associated with higher plasma PTX3 concentrations （r = -0.29, P = 0.02）. Furthermore, lower PTX3 promoter methylation levels were associated with higher neutrophil to lymphocyte ratio （NLR） in men （r = -0.58, P = 0.002）. Conclusions The present study provides new evidence that methylation of the PTX3 promoter is associated with PTX3 plasma levels and NLR in coronary artery disease. This study also shows that modification of epigenetics by chronic inflamma- tion might be a significant molecular mechanism in the atherosclerotic processes that influence plasma PTX3 concentrations.展开更多
Objective To determine whether the onset of acute lung injury （ALl） induces the up-regulation of pentraxin 3 （PTX3） expression in mice and whether PTX3 concentration in the biofluid can help recognizing sepsis-ind...Objective To determine whether the onset of acute lung injury （ALl） induces the up-regulation of pentraxin 3 （PTX3） expression in mice and whether PTX3 concentration in the biofluid can help recognizing sepsis-induced ALI. Methods Wild-type C57BL/6 mice （12-14 weeks old） were randomly divided into 3 groups. Mice in the group 1 （n=12） and group 2 （n=12） were instilled with lipopolysaccharide via intratracheal or intraperitoneal routes, respectively. Mice in the group 3 （n=8） were taken as blank controls. Pulmonary morphological and functional alterations were measured to determine the presence of experimental ALl. PTX3 expression in the lung was quantified at both protein and mRNA levels. PTX3 protein concentration in blood and bronchoalveolar lavage fluid was measured to evaluate its ability to diagnose sepsis-induced ALI by computing area under receiver operator characteristic curve （AUROCC）. Results ALl was commonly confirmed in the group 1 but never in the other groups. PTX3 expression was up-regulated indiscriminately among lipopolysaccharide-challenged mice. PTX3 protein concentration in the biofluid was unable to diagnose sepsis-induced ALl evidenced by its small AUROCC. PTX3 concentration in bronchoalveolar lavage fluid did not correlate with that in serum. Conclusions Lipopolysaccharide challenges induced PTX3 expression in mice regardless of the presence ofALI. PTX3 may act as an indicator of inflammatory response instead of organ injury per se.展开更多
Background: Clinical data suggested that pentraxin-3 is a biomarker for atherosclerosis due to its role in inflammatory processes since it exerts unfavorable effects on the course of atherosclerosis, stimulates plaque...Background: Clinical data suggested that pentraxin-3 is a biomarker for atherosclerosis due to its role in inflammatory processes since it exerts unfavorable effects on the course of atherosclerosis, stimulates plaque formation, and augments vascular inflammation. Objective: The aims of this study were to measure the level of serum pentraxin-3 in patients with suspected coronary artery disease (CAD) and to determine whether it was associated with the severity of CAD. Material and Methods: The serum pentraxin-3 level was measured by enzyme-linked immunosorbent assay in 80 patients who were referred for elective coronary angiography due to positive stress test results. SYNTAX score was used to determine the severity of CAD. Results: The study cohort consisted of 45 (56.25%) males and 35 (43.75%) females with a mean age of 55 ± 9.8 years. The mean serum pentraxin-3 level was 3.79 ± 1.38 ng/ml, and the mean SYNTAX score was 15.8 ± 11.3. A significant correlation was observed between pentraxin-3 level and SYNTAX score (r = 0.459, p - 32 or ≤22 (p = 0.002). Conclusion: The serum level of inflammatory marker pentraxin-3 is increased in patients with CAD and is correlated with the severity of CAD.展开更多
Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment ele...Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment elevation myocardial infarction (STEMI), to investigate correlation with the left ventricular (LV) systolic function assessed by speckle tracking echocardiography, and compare with the well-established cardiac biomarkers of myocardial injury such as troponin-I. Methods: Serum pentraxin-3 level was measured by ELISA in 50 patients with anterior STEMI. LV strain was measured by speckle tracking echocardiography. The results were compared to twenty sex- and age-matched persons who had history of stable angina and normal LV ejection fraction (LVEF). Results: Serum level of pentraxin-3 was significantly higher in STEMI patients in comparison to the control group (8.3 ± 3.1 versus 3.4 ± 1.2 ng/ml, p 0.001). Average LV global longitudinal strain (GLS) was reduced in STEMI patients in comparison to control subjects (11.2 ± 2.4 versus 20.2 ± 2.1, p 0.001). In addition, there was a significant negative correlation between serum pentraxin-3 level and LVEF (r = -0.557, p 0.001) and the average LVGLS (r =-0.529, p 0.001). Serum pentraxin-3 cutoff value > 8.3 ng/ml had sensitivity of 81.8% and specificity of 86.4% to detect LVEF less than 50% (p 0.001). While, peak cardiac troponin-I level > 34 ng/ml was 86% sensitive to detect LVEF less than 50% with specificity of 90.9%. Conclusions: The elevated serum level of pentraxin-3 and cardiac troponin-I in STEMI patients and their association with both LVEF and GLS support the concept that the magnitude of these biomarkers correlates to the severity of myocardium injury.展开更多
基金Supported by 2022 Educational Research Program for Young and Middle-aged Teachers in Fujian Province(Science and Technology),No.JAT220107.
文摘BACKGROUND Cognitive dysfunction in epileptic patients is a high-incidence complication.Its mechanism is related to nervous system damage during seizures,but there is no effective diagnostic biomarker.Neuronal pentraxin 2(NPTX2)is thought to play a vital role in neurotransmission and the maintenance of synaptic plasticity.This study explored how serum NPTX2 and electroencephalogram(EEG)slow wave/fast wave frequency ratio relate to cognitive dysfunction in patients with epilepsy.AIM To determine if serum NPTX2 could serve as a potential biomarker for diagnosing cognitive impairment in epilepsy patients.METHODS The participants of this study,conducted from January 2020 to December 2021,comprised 74 epilepsy patients with normal cognitive function(normal group),37 epilepsy patients with cognitive dysfunction[epilepsy patients with cognitive dysfunction(ECD)group]and 30 healthy people(control group).The minimental state examination(MMSE)scale was used to evaluate cognitive function.We determined serum NPTX2 levels using an enzyme-linked immunosorbent kit and calculated the signal value of EEG regions according to the EEG recording.Pearson correlation coefficient was used to analyze the correlation between serum NPTX2 and the MMSE score.RESULTS The serum NPTX2 level in the control group,normal group and ECD group were 240.00±35.06 pg/mL,235.80±38.01 pg/mL and 193.80±42.72 pg/mL,respectively.The MMSE score was lowest in the ECD group among the three,while no significant difference was observed between the control and normal groups.In epilepsy patients with cognitive dysfunction,NPTX2 level had a positive correlation with the MMSE score(r=0.367,P=0.0253)and a negative correlation with epilepsy duration(r=−0.443,P=0.0061)and the EEG slow wave/fast wave frequency ratio value in the temporal region(r=−0.339,P=0.039).CONCLUSION Serum NPTX2 was found to be related to cognitive dysfunction and the EEG slow wave/fast wave frequency ratio in patients with epilepsy.It is thus a potential biomarker for the diagnosis of cognitive impairment in patients with epilepsy.
文摘Objective: Coronary Artery Disease (CAD) would continue to concern medical society in the foreseeable future. Determining the extent of coronary luminal stenosis is a key factor in management of CAD. Methods presently used are costly and pose certain dangers, ranging from nephrotoxicity to death. Long Pentraxin or Pentraxin-3 (PTX3) has been used to predict survival or atherosclerotic process, but not to identify coronary stenosis. Calcium Score has been used to this end with some success. Methods: Individuals with chronic stable angina, without evidence of Myocardial Infarction (MI), who were categorized as intermediate-risk after completing a treadmill exercise test, according to Duke Protocol, underwent cardiac catheterization. In addition, blood samples were drawn for coronary sinus PTX3, and also PTX3, uric acid, high-sensitivity C-reactive protein (hs-CRP), cholesterol, glucose and High-Density Lipo-protein (HDL) in peripheral circulation. Calcium Scores were calculated using Agatston Score and non-contrast multi-slice CT scan. Participants were divided according to the number of stenotic coronary arteries (patent, one-, two-and three-vessel disease). Results: We found that PTX3 levels in coronary sinus and femoral vein correlated with each other, after log-transforming the values. Also we found that PTX3 levels and Calcium Scores differed among individuals with triple-vessel involvement and individuals without significant stenosis in any of coronary arteries. No significant differences were observed, regarding hs-CRP levels. Conclusion: PTX3 levels in periphery correlate with those in coronary arteries, and this variable can be measured with a less invasive procedure. In addition to Calcium Score, PTX3 levels are different in our four groups. The combined contribution of PTX3 and calcium score may help us identify individuals with significant coronary artery stenosis without needing to perform cardiac catheterization in a select group of patients.
文摘Background Pentraxin 3 （PTX3） is expressed in the heart under inflammatory conditions and plays an important role in atherogenesis. Patients with increased PTX3 levels may suffer from higher rates of cardiac events. Regulation of specific genes by promoter methylation is important in atherogenesis. The factors influencing PTX3 levels and the association between epigenetics and PTX3 levels have not been investigated. Methods Blood samples were collected from 64 patients admitted to the Department of Cardiology, 35 who had coronary artery disease （CAD）, and 29 who were CAD-free. Plasma levels of PTX3 were measured by ELISA. PTX3 promoter methylation was evaluated via methyl-specific PCR. The severity of coronary artery lesion was evaluated by angiography. Results The level of PTX3 promoter methylation in the CAD group was 62.69% ± 20.57%, significantly lower than that of the CAD-free group, which was 72.45% ± 11.84% （P = 0.03）. Lower PTX3 promoter methylation levels in the CAD group were associated with higher plasma PTX3 concentrations （r = -0.29, P = 0.02）. Furthermore, lower PTX3 promoter methylation levels were associated with higher neutrophil to lymphocyte ratio （NLR） in men （r = -0.58, P = 0.002）. Conclusions The present study provides new evidence that methylation of the PTX3 promoter is associated with PTX3 plasma levels and NLR in coronary artery disease. This study also shows that modification of epigenetics by chronic inflamma- tion might be a significant molecular mechanism in the atherosclerotic processes that influence plasma PTX3 concentrations.
基金Partly supported by a grant from Jie-shou Li Academician Gut Barrier Research Fund
文摘Objective To determine whether the onset of acute lung injury （ALl） induces the up-regulation of pentraxin 3 （PTX3） expression in mice and whether PTX3 concentration in the biofluid can help recognizing sepsis-induced ALI. Methods Wild-type C57BL/6 mice （12-14 weeks old） were randomly divided into 3 groups. Mice in the group 1 （n=12） and group 2 （n=12） were instilled with lipopolysaccharide via intratracheal or intraperitoneal routes, respectively. Mice in the group 3 （n=8） were taken as blank controls. Pulmonary morphological and functional alterations were measured to determine the presence of experimental ALl. PTX3 expression in the lung was quantified at both protein and mRNA levels. PTX3 protein concentration in blood and bronchoalveolar lavage fluid was measured to evaluate its ability to diagnose sepsis-induced ALI by computing area under receiver operator characteristic curve （AUROCC）. Results ALl was commonly confirmed in the group 1 but never in the other groups. PTX3 expression was up-regulated indiscriminately among lipopolysaccharide-challenged mice. PTX3 protein concentration in the biofluid was unable to diagnose sepsis-induced ALl evidenced by its small AUROCC. PTX3 concentration in bronchoalveolar lavage fluid did not correlate with that in serum. Conclusions Lipopolysaccharide challenges induced PTX3 expression in mice regardless of the presence ofALI. PTX3 may act as an indicator of inflammatory response instead of organ injury per se.
文摘Background: Clinical data suggested that pentraxin-3 is a biomarker for atherosclerosis due to its role in inflammatory processes since it exerts unfavorable effects on the course of atherosclerosis, stimulates plaque formation, and augments vascular inflammation. Objective: The aims of this study were to measure the level of serum pentraxin-3 in patients with suspected coronary artery disease (CAD) and to determine whether it was associated with the severity of CAD. Material and Methods: The serum pentraxin-3 level was measured by enzyme-linked immunosorbent assay in 80 patients who were referred for elective coronary angiography due to positive stress test results. SYNTAX score was used to determine the severity of CAD. Results: The study cohort consisted of 45 (56.25%) males and 35 (43.75%) females with a mean age of 55 ± 9.8 years. The mean serum pentraxin-3 level was 3.79 ± 1.38 ng/ml, and the mean SYNTAX score was 15.8 ± 11.3. A significant correlation was observed between pentraxin-3 level and SYNTAX score (r = 0.459, p - 32 or ≤22 (p = 0.002). Conclusion: The serum level of inflammatory marker pentraxin-3 is increased in patients with CAD and is correlated with the severity of CAD.
文摘Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment elevation myocardial infarction (STEMI), to investigate correlation with the left ventricular (LV) systolic function assessed by speckle tracking echocardiography, and compare with the well-established cardiac biomarkers of myocardial injury such as troponin-I. Methods: Serum pentraxin-3 level was measured by ELISA in 50 patients with anterior STEMI. LV strain was measured by speckle tracking echocardiography. The results were compared to twenty sex- and age-matched persons who had history of stable angina and normal LV ejection fraction (LVEF). Results: Serum level of pentraxin-3 was significantly higher in STEMI patients in comparison to the control group (8.3 ± 3.1 versus 3.4 ± 1.2 ng/ml, p 0.001). Average LV global longitudinal strain (GLS) was reduced in STEMI patients in comparison to control subjects (11.2 ± 2.4 versus 20.2 ± 2.1, p 0.001). In addition, there was a significant negative correlation between serum pentraxin-3 level and LVEF (r = -0.557, p 0.001) and the average LVGLS (r =-0.529, p 0.001). Serum pentraxin-3 cutoff value > 8.3 ng/ml had sensitivity of 81.8% and specificity of 86.4% to detect LVEF less than 50% (p 0.001). While, peak cardiac troponin-I level > 34 ng/ml was 86% sensitive to detect LVEF less than 50% with specificity of 90.9%. Conclusions: The elevated serum level of pentraxin-3 and cardiac troponin-I in STEMI patients and their association with both LVEF and GLS support the concept that the magnitude of these biomarkers correlates to the severity of myocardium injury.
